Clinical trials: Systemic Treatment
Cachexia, Lymphoma
Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer
RATIONALE: Celecoxib may help relieve moderate or severe pain associated with cancer. It may also decrease weight loss and improve muscle strength in cancer patients.
- Conditions
- Cachexia, Lymphoma, Melanoma (Skin), Ovarian Cancer
- Trial name
- NCT00093678
- Testing
- celecoxib, anticachectic therapy, nutritional support
- Sponsor
- Eastern Cooperative Oncology Group
Breast Cancer
Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib as Primary Systemic Treatment in Breast Cancer Patients
Endocrine therapy is the mainstay of systemic treatment in patients with endocrine responsive breast cancer. Aromatase inhibitors are the most active agents in post-menopausal women.
- Trial name
- NCT00954135
- Testing
- letrozolo+cyclophosphamide, letrozolo+sorafenib+cyclophosphamide
- Where
- 2 sites in Italy
- Volunteers
- 190 people
- Sponsor
- University of Turin, Italy
Lupus Nephritis
A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis
To demonstrate that the treatment effect in lupus nephritis of MZR is non-inferior to that of standard therapy CTX through analyzing overall remission rate after treatment.
- Trial name
- NCT02256150
- Testing
- Mizoribine (MZR), Cyclophosphamide (CTX)
- Where
- 26 sites in China
- Volunteers
- 250 people
- Sponsor
- Asahi Kasei Therapeutics Corporation
Head and Neck Disorder, Head and Neck Cancer
Bevonescein for Improved Intraoperative Nerve Visualization to Improve Voice Outcomes in Thyroidectomy Patients
Bevonescein (ALM-488) is a novel fluorescein-containing peptide that is intended as a visualization adjunct for the real-time enhanced structural delineation of major nerves during Head and Neck surgery to potentially improve…
- Trial name
- NCT07631650
- Testing
- Bevonescein (ALM 488) Infusion
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Matthew Spector
Uveitis, Cancer
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study
This study will evaluate whether therapy that suppresses the immune system given to treat inflammatory diseases of the eye is associated with a greater risk of death and of cancer.
- Conditions
- Uveitis, Cancer, Infection, Mortality
- Trial name
- NCT00116090
- Where
- 4 sites in United States
- Volunteers
- 6,300 people
- Sponsor
- National Eye Institute (NEI)
Septic Shock
Norepinephrine Weaning in Septic Patients
The weaning rate of vasopressors drugs is usually chosen empirically by the clinician in critically patients. The investigators applied fuzzy logic principles to modify intravenous norepinephrine infusion rates during…
- Trial name
- CATECHOFLOU (NCT00763906)
- Testing
- norepinephrine infused at the clinician's discretion, norepinephrine infused under computerized fuzzy logic control
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Association pour le Développement de la Recherche et de l'Enseignement en Médecine d'Urgence
Hepatocellular Carcinoma Non-resectable, Effect of Drug
Predicting Response to Systemic Therapies for Hepatocellular Carcinoma(HCC)
As the most common type of primary liver cancer, hepatocellular carcinoma (HCC) has become a big challenge all over the world. Most patients are not available to curative resection when first diagnosed.
- Trial name
- NCT05543304
- Testing
- radiological evaluation
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Systemic Lupus Erythematosus, Pulmonary Arterial Hypertension
Anti-CD20 Antibodies for Treatment of SLE-PAH
This is a prospective, single-arm, single-center, explorative clinical trial to evaluate the effect of Rituximab on disease progression in subjects with SLE-PAH receiving concurrent stable-dose standard medical therapy.
- Trial name
- NCT05828147
- Testing
- Rituximab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chinese SLE Treatment And Research Group
Patient Reported Outcome Measure
Safer Personalised Cancer Treatment Digital Follow-up
The goal of this clinical trial is to investigate patient harm/ adverse events, overall survival and health related quality of life under treatment with immunotherapy medication in cancer patients when they are followed up by a…
- Trial name
- SPecT (NCT06476158)
- Testing
- Kaiku Health
- Where
- Norway
- Volunteers
- 900 people
- Sponsor
- Nordlandssykehuset HF
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00004904
- Testing
- anti-thymocyte globulin, filgrastim, cladribine
- Where
- United States
- Sponsor
- Northwestern University
Periodontal Diseases, Aggressive Periodontitis
Influence of Smoking on Clinical, Microbiological and Immunologic Parameters in Patients With Aggressive Periodontitis.
Treatment of smoker patients with AgP is considered a challenge to periodontists. To date, only one controlled clinical study (De Genaro Modanese et al., 2016) evaluated the effect of full mouth ultrasonic debridment (FMUD) on…
- Trial name
- NCT04051255
- Testing
- full mouth ultrassonic debridement associated to Amoxicilin 500 + Metronidazole 400 mg
- Where
- Brazil
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Campinas, Brazil
Cerebral Stroke, Thrombosis, Deep Vein
A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery
To characterize and analyze the number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with Apixaban, according to therapeutic indications approved in Mexico.
- Conditions
- Cerebral Stroke, Thrombosis, Deep Vein, Pulmonary Embolism
- Trial name
- NCT03804125
- Sponsor
- Pfizer
Septic Shock, Fluid Therapy
Fluid Balance in the ICU - Interventions to Minimize Fluids in Patients With Septic Shock
The purpose of the study is to determine if a protocol that assesses patients' daily fluid intake and output can decrease the overall amount of fluid patients receive during the first five days in the ICU.
- Conditions
- Septic Shock, Fluid Therapy, Hypotension
- Trial name
- NCT02473718
- Testing
- Fluid minimization protocol, Ultrasound
- Volunteers
- 82 people
- Sponsor
- Washington University School of Medicine
Interstitial Lung Disease, Connective Tissue Disease
A Clinical Trial for CTD-ILD Treatment
The first objective of this protocol is to assess the tolerability and safety of N-acetylcysteine (NAC) in patients with connective tissue disease related interstitial lung disease (CTD-ILD).
- Trial name
- NCT01424033
- Testing
- N-Acetylcysteine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Michigan
Systemic Lupus Erythematosus, Muscle Pain
Laser Therapy for Patients With Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease that has detrimental effects on connective tissue and other organs.
- Conditions
- Systemic Lupus Erythematosus, Muscle Pain, Chewing Function
- Trial name
- NCT04453215
- Testing
- GaAlAs semiconductor diode laser device
- Where
- Turkey (Türkiye)
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Dr. Merve Benli
Lupus Nephritis
To Compare the Efficacy and Safety of FK506 vs IVC in the Treatment of Class III-IV LN
1. To compare the efficacy of FK506 vs intravenous cyclophosphamide pulses in the treatment of class III-IV LN. 2. To compare the safety and tolerability of FK506 vs intravenous cyclophosphamide pulses in the treatment of class…
- Trial name
- NCT00302549
- Testing
- FK506
- Where
- China
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Nanjing University School of Medicine
Autoimmune Diseases, SLE - Systemic Lupus Erythematosus
RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases
This is a single-arm, open-label, phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-05, a universal CD19/BCMA dual-targeting chimeric antigen receptor T-cell…
- Conditions
- Autoimmune Diseases, SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis, IIM- Idiopathic Inflammatory Myopathies
- Trial name
- NCT07674147
- Testing
- RD06-05 CART Cell Infusion
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Septic Shock
The Effect of Restrictive Fluid Management on Cardiac Function and Glycocalyx Degradation
The study aims to compare the effects of restrictive fluid management on cardiac dysfunction and vascular integrity in septic shock patients.
- Trial name
- NCT04282252
- Testing
- I.V. SOLUTIONS
- Where
- Sweden
- Volunteers
- 54 people
- Sponsor
- Karolinska Institutet
Prostate Cancer
Impact of Radical Prostatectomy as Primary Treatment in Patients With Prostate Cancer With Limited Bone Metastases
The aim of the study is to investigate, the effect of radical prostatectomy with extended lymphadenectomy on cancer-specific survival, time to castration-resistance, time to progression and quality of life in patients with a…
- Trial name
- g-RAMPP (NCT02454543)
- Testing
- Radical prostatectomy, Best systemic therapy
- Where
- Germany
- Volunteers
- 452 people
- Sponsor
- Martini-Klinik am UKE GmbH
Immune System Diseases, Premature Infant Disease
Oral Colostrum and Its Effect on Immune System
The purpose of this project is to increase the serum immunological defenses of premature infants less then 32 weeks of gestation by administrating colostrum in the oropharyngeal mucosa versus placebo
- Conditions
- Immune System Diseases, Premature Infant Disease, Immunoglobulin Deficiency
- Trial name
- NCT03578341
- Testing
- Orally Colostrum
- Where
- 2 sites in Mexico
- Volunteers
- 96 people
- Sponsor
- Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.